Factor VIII (FVIII) replacement therapy remains the mainstay in hemophilia A care. The major
complication of replacement therapy is formation of antibodies, which inhibit FVIII activity …

Acquired haemophilia A (AHA) is a rare bleeding disorder characterized by the sudden
generation of autoantibodies against factor VIII (FVIII) in individuals with no previous history …

Dilated cardiomyopathy (DCM) is a myocardial disease characterized by progressive
depression of myocardial contractile function and ventricular dilatation. Thirty percent of …

Previous studies identified nonneutralizing FVIII-specific antibodies in the circulation of
severe and nonsevere hemophilia A (sHA and nsHA) patients without FVIII inhibitors and …

Adequate hemostasis is achieved for many hemophilia A patients by infusion of plasma-
derived or recombinant factor VIII (FVIII), but unfortunately, a significant subset of patients …

BACKGROUND AND OBJECTIVES. The development of neutralizing anti-factor VIII
antibodies (a-fVIII) is a major clinical complication. Lupus anticoagulant (LA) might affect …

Anti-factor VIII (FVIII) inhibitory IgG may arise as allo-antibodies to therapeutic FVIII in
patients with congenital hemophilia A, or as auto-antibodies to endogenous FVIII in …

Intravenous immunoglobulin (IVIG) preparations are derived from the pooled plasma of
thousands of healthy donors and contain a complex mix of antibodies. Depending on the …

В обзоре приведены собственные данные и сведения литературы о роли аутоантител
к факторам свертывания крови, естественным антикоагулянтам и фибринолитическим …

The root cause of autoantibody formation against factor VIII (FVIII) in acquired hemophilia A
(AHA) remains unclear. We aimed to assess whether AHA is exclusively associated with …